BR0204160A - Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico - Google Patents

Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico

Info

Publication number
BR0204160A
BR0204160A BR0204160-0A BR0204160A BR0204160A BR 0204160 A BR0204160 A BR 0204160A BR 0204160 A BR0204160 A BR 0204160A BR 0204160 A BR0204160 A BR 0204160A
Authority
BR
Brazil
Prior art keywords
cyclopaladate
modulating
compound
composition
immune system
Prior art date
Application number
BR0204160-0A
Other languages
English (en)
Inventor
Antonio Carlos Favero Caires
Claudia Bincoletto Trindade
Ivarne Luis Dos Sant Tersariol
Original Assignee
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao De Amparo A Pesquisa filed Critical Fundacao De Amparo A Pesquisa
Priority to BR0204160-0A priority Critical patent/BR0204160A/pt
Priority to US10/525,781 priority patent/US7432403B2/en
Priority to DE60334623T priority patent/DE60334623D1/de
Priority to EP03790577A priority patent/EP1534257B1/en
Priority to ES03790577T priority patent/ES2353961T3/es
Priority to CN038247240A priority patent/CN1741797B/zh
Priority to PCT/BR2003/000120 priority patent/WO2004019924A1/en
Priority to MXPA05002346A priority patent/MXPA05002346A/es
Priority to AU2003254432A priority patent/AU2003254432A1/en
Priority to JP2004531314A priority patent/JP2006510584A/ja
Priority to CA2496681A priority patent/CA2496681C/en
Priority to AT03790577T priority patent/ATE485036T1/de
Publication of BR0204160A publication Critical patent/BR0204160A/pt
Priority to US11/777,604 priority patent/US7935728B1/en
Priority to JP2010254009A priority patent/JP2011052008A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/006—Palladium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

"COMPOSTO CICLOPALADADO, COMPOSIçãO E UNIDADE DE DOSAGEM, SEUS USOS, MéTODO PARA INIBIR A ATIVIDADE DE PROTEìNAS E ENZIMAS E MéTODO DE TRATAMENTO DE DISTúRBIOS OU DOENçAS ASSOCIADAS àS MESMAS E MéTODO DE MODULAçãO DO SISTEMA IMUNOLóGICO". A presente invenção trata de compostos ciclopaladados contendo ligantes bis-difenilfosfina-ferroceno e seus análogos como ativos inibidores de peptídeos e enzimas compreendendo as famílias de serino-peptidases, cisteino-proteases, metalo-proteases, endopeptidases, muitas das quais essenciais no mecanismo de desenvolvimento e metástase de tumores malignos. Atuando sobre essas enzimas e participando de intercalações com moléculas de DNA, esses compostos modulam o sistema imunológico.
BR0204160-0A 2002-08-30 2002-08-30 Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico BR0204160A (pt)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BR0204160-0A BR0204160A (pt) 2002-08-30 2002-08-30 Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico
MXPA05002346A MXPA05002346A (es) 2002-08-30 2003-08-22 Compuestos ciclicos de paladio teniendo coordinados con ellos ligandos de bis (difenilfosfina) ferroceno que inhiben la actividad de proteinas y enzimas, y tratamiento de enfermedades y desordenes asociados con ellas.
AU2003254432A AU2003254432A1 (en) 2002-08-30 2003-08-22 Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith.
EP03790577A EP1534257B1 (en) 2002-08-30 2003-08-22 Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith.
ES03790577T ES2353961T3 (es) 2002-08-30 2003-08-22 Compuesto de ciclopaladio, composición y unidad de dosificación , sus usos, método para inhibir la actividad de proteínas y enzimas, método de tratamiento para el transtornos o enfermedades asociadas a los mismos y método de modulación para el sistema inmunológico.
CN038247240A CN1741797B (zh) 2002-08-30 2003-08-22 抑制蛋白质和酶活性的具有配位的双(二苯基膦)二茂铁配体的环钯化合物
PCT/BR2003/000120 WO2004019924A1 (en) 2002-08-30 2003-08-22 Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith.
US10/525,781 US7432403B2 (en) 2002-08-30 2003-08-22 Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith
DE60334623T DE60334623D1 (de) 2002-08-30 2003-08-22 ZYKLISCHE PALLADIUM-VERBINDUNGEN MIT DAMIT KOORDINIERTEN BIS (DIPHENYLPHOSPHIN)-FERROCEN-LIGANDEN ZUR HEMMUNG DER AKTIVITuT VON PROTEINEN UND ENZYMEN UND BEHANDLUNG VON DAMIT ZUSAMMENHuNGENDEN KRANKHEITEN UND ST RUNGEN.
JP2004531314A JP2006510584A (ja) 2002-08-30 2003-08-22 タンパク質および酵素の活性を阻害するビス（ジフェニルホスフィン）フェロセン・リガンドが配位した環状パラジウム化合物ならびにそれに関係した疾患および異常の処置
CA2496681A CA2496681C (en) 2002-08-30 2003-08-22 Cyclopalladated compounds comprising bis-diphenylphosphine-ferrocene ligands, and their use in treating diseases
AT03790577T ATE485036T1 (de) 2002-08-30 2003-08-22 Zyklische palladium-verbindungen mit damit koordinierten bis (diphenylphosphin)-ferrocen- liganden zur hemmung der aktivitut von proteinen und enzymen und behandlung von damit zusammenhungenden krankheiten und st rungen.
US11/777,604 US7935728B1 (en) 2002-08-30 2007-07-13 Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith
JP2010254009A JP2011052008A (ja) 2002-08-30 2010-11-12 タンパク質および酵素の活性を阻害するビス（ジフェニルホスフィン）フェロセン・リガンドが配位した環状パラジウム化合物ならびにそれに関係した疾患および異常の処置

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0204160-0A BR0204160A (pt) 2002-08-30 2002-08-30 Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico

Publications (1)

Publication Number Publication Date
BR0204160A true BR0204160A (pt) 2004-06-01

Family

ID=31954473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204160-0A BR0204160A (pt) 2002-08-30 2002-08-30 Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico

Country Status (12)

Country Link
US (2) US7432403B2 (pt)
EP (1) EP1534257B1 (pt)
JP (2) JP2006510584A (pt)
CN (1) CN1741797B (pt)
AT (1) ATE485036T1 (pt)
AU (1) AU2003254432A1 (pt)
BR (1) BR0204160A (pt)
CA (1) CA2496681C (pt)
DE (1) DE60334623D1 (pt)
ES (1) ES2353961T3 (pt)
MX (1) MXPA05002346A (pt)
WO (1) WO2004019924A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521512D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
JP5161434B2 (ja) * 2006-05-19 2013-03-13 日本化学工業株式会社 抗癌剤
ATE411375T1 (de) 2006-07-27 2008-10-15 Evonik Degussa Gmbh Umhüllte natriumpercarbonatpartikel
CA2670837C (en) * 2006-12-18 2016-03-29 Jack Arbiser Novel palladium complexes inhibit n-myristoyltransferase activity in vitro and cancer growth in vivo
US7390915B1 (en) * 2007-08-20 2008-06-24 Nippon Chemical Industrial Co., Ltd Phosphine transition metal complex having ferrocene skeleton, process for making the same, and anti-cancer agent
CN101559076B (zh) * 2009-05-27 2012-08-29 西北大学 抗肿瘤基质金属蛋白酶抑制剂
US9839643B2 (en) 2014-05-09 2017-12-12 Uludag Üniversitesi Tto Palladium complex with high anticancer activity
CN116162127B (zh) * 2023-02-20 2023-06-23 中国医学科学院阜外医院 一种颗粒酶b靶向抑制剂和探针及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584316A (en) * 1983-03-25 1986-04-22 Research Corporation Palladium anti-cancer complexes
US5618983A (en) * 1995-08-25 1997-04-08 E. I. Du Pont De Nemours And Company Hydroformylation process
US5880149A (en) 1995-09-28 1999-03-09 California Institute Of Technology Metal complexes as cysteine protease inhibitors

Also Published As

Publication number Publication date
MXPA05002346A (es) 2005-11-04
AU2003254432A1 (en) 2004-03-19
CA2496681C (en) 2014-08-05
CN1741797B (zh) 2013-07-24
EP1534257A1 (en) 2005-06-01
US7432403B2 (en) 2008-10-07
CA2496681A1 (en) 2004-03-11
EP1534257B1 (en) 2010-10-20
US7935728B1 (en) 2011-05-03
JP2011052008A (ja) 2011-03-17
ES2353961T3 (es) 2011-03-08
US20060106100A1 (en) 2006-05-18
WO2004019924A1 (en) 2004-03-11
ATE485036T1 (de) 2010-11-15
JP2006510584A (ja) 2006-03-30
DE60334623D1 (de) 2010-12-02
CN1741797A (zh) 2006-03-01

Similar Documents

Publication Publication Date Title
Lum et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
Endres et al. Tumor necrosis factor‐α converting enzyme is processed by proprotein‐convertases to its mature form which is degraded upon phorbol ester stimulation
Ito et al. Degradation of interleukin 1β by matrix metalloproteinases
Gooyit et al. A chemical biological strategy to facilitate diabetic wound healing
Tucher et al. LC–MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries
Aimes et al. Matrix metalloproteinase-2 is an interstitial collagenase: inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type i collagen generating the specific ¾-and ¼-length fragments (∗)
Garnero et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases
Han et al. Tumor necrosis factor-α-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase
Gutwein et al. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells
Nguyen et al. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility
Fu et al. Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases
Roghani et al. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity
Lowe The structure and mechanism of action of papain
Cao et al. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A
Szabó et al. Determinants of chymotrypsin C cleavage specificity in the calcium‐binding loop of human cationic trypsinogen
Hahn et al. Phorbol 12-myristate 13-acetate-induced ectodomain shedding and phosphorylation of the human meprinβ metalloprotease
Ferrer-Montiel et al. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins
ATE226588T1 (de) Phosphinsäure-derivate
BR0204160A (pt) Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico
Kremer et al. Hydroxyapatite induces autolytic degradation and inactivation of matrix metalloproteinase‐1 and‐3
Ries et al. Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells:(auto-) catalytic activation and resistance to inhibition by TIMP-1
Kohno et al. Immunoaffinity purification and characterization of leucine aminopeptidase from human liver.
Ali et al. Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17
Schlomann et al. Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays
Chen et al. A residue in the S2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]